List of exhibitors

5.9 S.r.l. is an Italian leading company of weighing systems for medical applications. Monitoring the patient’s weight during invasive medical treatments, such as dialysis, allows the medical staff to verify the patient’s health conditions just in a glance. We developed an integrated weighing system with touch display, able to create a dedicated patient file, complete with the treatment information and the patient medical history.
Our product range includes bed scales and armchair scales, and also dedicated and customizable weighing systems in accordance with any customer need.
Moreover, we recently developed a brand-new mobile weighing system that can be added and adapted to any medical furniture already in usage in hospitals.

Advicenne is dedicated to developing innovative, effective and safe treatments for people living with rare renal diseases who have very limited therapeutic options. Thanks to our expertise in reformulation and drug delivery, we are uniquely positioned to develop and make available innovative treatments for both children and adults.
We are dedicated to improving patients’ daily health and life and are committed to tackle the challenge of high unmet medical needs.
Sibnayal® (combination of Potassium citrate and Potassium bicarbonate) has received its Marketing Approval for distal renal tubular acidosis (dRTA) in EU and GB. Sibnayal® is approved for both the genetic and acquired form of dRTA. For more information, visit www.advicenne.com

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

Allmed is a vertically integrated global manufacturer, selling and operating in over 40 countries around the world.
Allmed has a wide product range in the haemodialysis consumables market space, and is home to multiple patented and innovative products, including:
– The market’s only steam-autoclaved Polysulfone dialyzer range
– A special therapy BIOREMA® 26H high-capacity filtration product line, as well as
– The BIOCARB-G: a bicarbonate cartridge whose patented design allows it to enjoy the lowest carbon footprint of any comparable product on the market.

We are committed to offering customised solutions to Haemodialysis professionals and patients in.

Alnylam is leading the translation of RNA interference into a whole class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious and central nervous system and ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for treating a wide range of severe, debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam is headquartered in Cambridge, MA.

Alnylam has funded the scientific medical educational part of the meeting only.

Alpine Immune Sciences is leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives.

Our lead development program is povetacicept, a dual antagonist of the BAFF and APRIL cytokines, which play key roles in pathogenesis of multiple autoimmune diseases via their roles in the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Based upon an engineered TACI (transmembrane activator and CAML interactor) domain, povetacicept has exhibited greater potency in preclinical studies versus other inhibitors of BAFF and/or APRIL alone and B cell depletion. Povetacicept is in development for multiple autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy and other autoimmune kidney diseases and autoimmune cytopenias. For more information, visit www.alpineimmunesciences.com.

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge medicines for rare metabolic diseases.

In Asahi Kasei’s medical enterprises, we have developed new medical devices and therapeutic technologies and made advances in biopharmaceutical and plasma derivative process engineering. We have achieved these through a high-level synergy of filtration and separation technologies using membranes, filters and adsorbents, together with wide-ranging knowledge and technological expertise in science, mechanical engineering and medical fields. Our filtration and separation technologies for blood and body fluids hold great promise as core technologies for integrative innovation.

The rapid evolution of technology and life sciences has brought new opportunities for scientists to develop ground-breaking research and make discoveries that improve and save people’s lives.

Astellas is working on the forefront of this healthcare change, combining our powerful mix of expertise, radical new science and technology with a relentless challenger spirit.

We are unusual in our ability to combine the experience, expertise and resources of an established company with the agility, flexibility and tenacity of a start-up. Relentless curiosity and a hunger for discovery flows throughout our entire organisation and is embedded in everything we do.

We take a patient-focused approach, that allows us to convert brilliant early science into treatments and solutions that directly improve and save patients’ lives. From lab to clinic to patient, we focus on the most promising science, empower the best talent to pursue it, and develop life-changing solutions alongside the best partners.

We pursue innovative science, focussing initially on the areas of greatest potential and then developing solutions where patient need is high, often in rare or under-served disease areas and in life-threatening or life-limiting diseases and conditions.

Delivering meaningful differences for patients is the driving force behind our EST-C team. We actively nurture an open and progressive culture, working with partners who share our passion to make a meaningful difference to the people who need it, by delivering treatments of value with the potential to improve health and redefine care.

Cardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca’s three therapy areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas , AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling comorbidities.

As one of the world’s leading medical technology companies, B. Braun protects and improves the health of people around the world. For over 180 years, the family-owned company has been accelerating progress in health care with pioneering spirit and groundbreaking contributions. This innovative strength continues to be the foundation of B. Braun’s success today—always with the goal of improving clinical outcomes, cost of care and patient benefits.

More than 65,000 employees live Sharing Expertise worldwide, they make B. Braun a true partner that develops smart solutions and sets new standards. By linking products, services and consulting, the company improves treatment processes and supports medical staff. In doing so, B. Braun always acts with future generations in mind, which is why responsibility for sustainable growth is embedded into all business processes. In 2022, the B. Braun Group generated sales of € 8.5 billion.

Bain Medical Equipment (Guangzhou) Co., Ltd., was established in 2003, is a leading manufacturer of medical equipment (consumables) for blood purification/hemodialysis treatment.

Headquartered in Huangpu District, Guangzhou. The Group Company has subsidiaries in Hong Kong, Taiwan, Turkey,Pakistan and India ect, with more than 3,000 employees worldwide.

The company is committed to the Research and Development, Manufacturing , Sales of device and disposables for blood purification. At present, the main products are Hollow Fiber Hemodialyzer, Tubing Sets for Hemodialysis, Disposable A.V. Fistula Needle Sets, Hemodialysis Machine, Disaposable Dialysis Care Kits, etc.

Aiming to be the best manufacturer in China , one of the top three worldwide in the field of blood purification, Bain Medical global sales network have been covered more than 80 countries and regions in Europe, Asia, the Middle East, Latin America, Africa and South America, The company is keeping moving ahead to a higher and stronger position, adhering to a quality policy of “Quality means a lot to life; Quality makes great achievement”and the purpose of ‘serving the people, contributing to the society’ and independent innovation.

Uniting to Save and Sustain Lives
Driven by our purpose, destined to transform.
Every day, millions of patients, caregivers and providers around the world rely on Baxter’s leading portfolio of diagnostic, critical care, nutrition, kidney care, hospital and surgical products and solutions. Everything we do converges at the critical intersection where products that save and sustain lives meet the healthcare professionals and caregivers who make it all happen.

With products, therapies and digital solutions available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.

www.baxter.com
https://www.linkedin.com/company/baxter-healthcare/
https://twitter.com/baxter_intl?

Bayer is a life science company and a global leader in healthcare and nutrition. Our innovative products support efforts to overcome the major challenges presented by a growing and aging global population.

Bayer is a life science company with three divisions:
– Crop Science / Innovative cropping systems, seed and trait technologies, sustainable crop protection, new fertilizers, carbon farming, data and digital solutions.
– Pharmaceuticals / Prescription products for cardiology, women’s healthcare, oncology, hematology, ophthalmology, radiology and other areas.
– Consumer Health / Non-prescription medicine in the categories of nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health.

For more information, go to www.bayer.com

Bio Preventive Medicine Corp. (BPM), a leading company in renal biomarker area, focuses on translating clinically validated and IP-protected (>79 patents) biomarkers into precision diagnostic solutions for unmet clinical needs. The disease area we focus on includes diabetic kidney disease (DKD), renal injury, and oncology.

Human uPTM3-DKD (DNlite-IVD103) ELISA test is a urinary prognosis test for predicting/monitoring risk of kidney disease progression, and it is perfect for routine clinical practice in any healthcare institutes and clinical labs. Besides precision management of DKD, it can also be applied for risk assessment of Acute Kidney Disease, and Graft Failure in kidney transplant patients.

Current DNlite-IVD103 has regulatory approvals in Europe, Taiwan, Malaysia, Thailand, Saudi Arabia and U.A.E. In addition, it is launched in Japan and US as RUO kit. Furthermore, several other worldwide regulatory approvals are in preparation.

Bionic Medizintechnik GmbH is located in Friedrichsdorf near Frankfurt/Main, Germany. We specialised for products in vascular access, therapy chairs and transfusion for more than 30 years. As a member of the JMS group we are the headquarter for all activities in Europe.

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at www.boehringer-ingelheim.com.

IgANexus is a peer-to-peer scientific education resource developed in collaboration with nephrology and immunology experts, funded by Calliditas Therapeutics AB. The mission of IgANexus is to advance awareness and understanding of pathophysiology and evidence-based care in IgA nephropathy.

Calliditas is dedicated to expanding treatment options and establishing new standards of care for people with rare diseases. By drawing on our expertise in pharmaceutical product development and leveraging our strategic partnerships, we quickly and efficiently identify, develop, and market a pipeline of innovative medicines that can improve the lives of patients. We successfully commercialized our lead candidate in the United States, and in collaboration with our partners, received approvals in Europe and Asia.

After 85 years of experience, Chiesi Group, a family-owned and run certified B Corporation company, launched Chiesi Global Rare Diseases in 2020.
Chiesi Global Rare Diseases is focused on research and development of treatments for rare and ultra-rare disorders. The Global Rare Diseases unit works in collaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available. The unit is also a dedicated partner with global leaders in patient advocacy, research and patient care.
Chiesi is the largest pharmaceutical group in the world to be awarded B Corp Certification.
B Corps are businesses that balance purpose with profit. They are legally required to consider the impact of their decisions on their workers, customers, suppliers, community, and the environment. This is a global movement of people using business as a force for good.

CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care). The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 32,000 people and delivers its lifesaving therapies to people in more than 100 countries
For more information about CSL Vifor, visit CSLVifor.com.

CytoSorbents is a critical care focused immunotherapy company using blood purification to modulate systemic inflammation – with the goal of preventing or treating multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption. CytoSorb® is distributed in more than 75 countries and has CE Mark approval in the EU for cytokine, bilirubin and myoglobin removal in numerous critical care applications and the removal of ticagrelor and rivaroxaban during cardiothoracic surgery. More than 220,000 individual applications have been performed worldwide.

We develop and market high-quality blood volume measurement devices. Our ambition is to make blood volume assessment a clinically applicable tool worldwide. We believe this to be highly beneficial to a great number of critically ill patients.

Detalo Health is founded in 2018 by Professor Carsten Lundby and Jonas Bechlund. Detalo is Esperanto for ‘detail’ and signifies the importance of precise and accurate blood volume quantification in medical treatment, as well as our dedication to quality first work ethos.

The development of the Detalo Clinical was initiated in 2015 and was based on a decade of experience with blood volume assessments in humans using various techniques. Prior to the launch of the device, numerous different prototypes had been constructed and tested. Today the Detalo devices are the only MDR-approved device that can be used to determine hemoglobin mass and blood volume in humans.

Based in Switzerland, Dialife is a global provider of high quality products, equipment and services for renal care. We offer a comprehensive range of devices and products for hemodialysis treatment, including dialysis machines, dialyzers, tubing sets, fistula needles, sodium bicarbonate cartridges, concentrates, disinfectants, endotoxin filters, on/off kits and more. We also provide turnkey solutions to set up dialysis clinics, as well as transfer technology services for the production of dialysis products.

Diasoft is your reliable partner for optimizing care around patients receiving dialysis treatment. Our Patient Management System Diamant integrates all disciplines involved in care: physicians, nurses, social workers and dieticians. Using your own PMS, our Connectivity Service provides bidirectional transfer of data from and to your dialysis devices. Our solutions are CE Marked as a Medical Device in Class 2 B under the MDR Over the years Diasoft solutions have has been in use in the majority of dialysis centres in The Netherlands, and in a growing number of centres in countries around the world.

Dimerix is an Australian publically traded (ASX: DXB) clinical-stage biopharmaceutical company, with a portfolio of drug candidates for inflammatory diseases, including kidney diseases.

Our lead candidate DMX-200 is currently in a global Phase III trial (ACTION3) for focal segmental glomerulosclerosis (FSGS).

Since 30 years, DWA has specialized in innovative solutions for the supply of high purity water to dialysis centers – worldwide. DWA develops systems for the production of ultrapure permeate and its distribution right to the dialysis machine. Our expertise in water treatment covers all aspects from the pre-treatment stages, through reverse osmosis, ultrafiltration and heat-disinfection systems, right up to the supply connection through to the dialysis machine. In addition, DWA offers systems for the distribution of acid and bicarbonate concentrates. Since its inception, DWA has been setting standards in dialysis water treatment and is the only company producing ultra-clean permeate by the combination of reverse osmosis and central ultrafiltration, including integrated simultaneous heat-disinfection of the ring mains to the dialysis machines. DWA is your global partner for the design, planning, installation, extension or conversion of dialysis centers and offers project management, installation and commissioning as well as service and maintenance from a single dedicated source.

EchoNous is pioneering a new category in POCUS – the only one to offer top-tier image quality + AI fueled interpretations, and cutting-edge innovations at the point-of-care. With cart benchmarked quality and advanced feature sets such as PW, CW, Color Doppler, and TDI, previously only seen on larger, more expensive systems, Kosmos ultraportable ultrasound is giving physicians a higher level of confidence in their bedside diagnosis.

Historically linked to the haemodialysis field, in the last years has dedicated its experience to other fields like, for example, chemotherapy. It is a dynamic and flexible company, which is willing to catch inputs from the market. Its proficiency, attention and service to the customer has allowed it to grow and to develop on the national and international market, throughout qualified partnerships.
The products are customized in each single characteristic, following customer’s needs.

Emodial develops advanced solutions for the vascular access management in dialysis: the Silver line of pads, plasters and pockets for CVCs, peritoneal catheters and PICCs releasing silver ions with antibacterial and anti-inflammatory action, also available in procedural kits for start/end treatment and, upon completion of advanced dressings, the innovative waterproof pockets for catheter, for bath and shower.

Etropal JSC is a leading company in the field of production of disposable medical devices since 1976.
Patient health is at the center of everything we do – and we follow this principle to meet the ever-increasing
demands on dialysis products, especially in the areas of design, working materials and manufacturing. As a medical device manufacturer, we give top priority to safety and reliability. All our medical products are certified according to the European Medical Devices Directive 93/42 / EEC. Production and sales are also part of an audited quality management system. In this way, it has firmly integrated quality assurance processes in all areas of work: from idea to market. In addition, continuous control at the various stages of production ensures consistently high quality of Etropal’s end products. With over thirty years of experience in the research and development and manufacturing of medical devices, Etropal offers a wide range of products for haemodialysis- dialysers, blood lines, fistula needles and other medical devices that meet the individual needs of each patient.

Eurofins Biomnis is a major player in specialised clinical diagnostics in Europe offering a variety of over 2,000 tests enabling physicians to make clear and reliable decisions. Clinical diagnostics is at the heart of therapeutic decisions thanks to screening, diagnosis, treatment response prediction and patient monitoring. Building on its 125 years of expertise, Eurofins Biomnis continue to innovate and use progress in molecular biology to offer tests with high medical added value for accurate and personalised patient management, particularly in nephrogenomics. Learn more at www.eurofins-biomnis.com – Contact : contact@biomnis.eurofinseu.com

Eurofins Transplant Diagnostics :
Through Pre-Transplant, Post-Transplant & Infectious Disease Management and Post-Transplant Rejection Biomarkers, we harness the power of four companies to meet your needs. We integrate: We harness the power of our network of companies to deliver comprehensive solutions across the transplant spectrum. We Innovate: We never stop moving forward and are always looking for solutions that will solve the complex challenges of tomorrow. We inform: We empower patients and providers to make informed decisions about current treatments and future therapies. Learn more at https://eurofinstransplant.com/ – Contact : Erica.Gifford@tgi.eurofinsus.com

FARMASOL is one of the successful players in hemodialysis market globally. It supports medical care all over world with a whole wide range of hemodialysis products and services. Since 2005, FARMASOL has continually evolved to advance high quality products in hemodialysis treatment, providing high quality and cost effective solutions to help people lead healthier lives. Our mission is to create better living conditions for our more than 500 patients under its roof as well as the patients all over the world by cooperating with doctors, employers and patients, bringing higher quality, safe and cost effective products. In order to have more detailed information regarding our current and new products please visit our booth D.400!

On-site booth:D.400

Fluid-o-Tech group is a leading supplier of technology to move, dose and sense fluid such as volumetric pumps, electronic valves, sensors and fluid systems in health technology field.

Fluid-o-Tech S.r.l is an Italian leading company with over seventy years of experience in the design and manufacture of positive displacement pumps and fluidics systems for accurately dosing and controlling fluids, for the medical, food service, automotive and many other mission critical fields.
The company with over 300 people worldwide and a direct presence in Italy, Germany, UK, USA, China, Japan and more than 120 distributors in over 60 countries, exports +80% of its production. Its factory is considered a model example for Industry 4.0. Quality and Innovation are the company strategic pillars, 5% of revenues are invested yearly in R&D involving 16% of its staff.
Fluid-o-Tech is a leading global supplier of fluidic solutions for the medical sector. It is committed to develop with its partners enabling technologies for medical devices to give access and improve therapies quality especially in the field of Health Tech.
Fluid-o-Tech positive displacement gear and peristaltic pumps are able to deliver precision flow. The gear pump range offers an impressive turn-down ratio and high pressure capability to meet your flushing and analytical needs.

In 2014, Dolphin Fluidics was born as an innovative startup within the Fluid-o-Tech Group by synergistically combining the Fluid-o-Tech Group’s experience in the precision fluid dynamics field with co-founder, Francesco Butera, 20 plus years of experience in the field of smart actuators based on shape memory alloys. Dolphin Fluidics is established with a specific pursuit: “to do what others do not do.” This iniative translate into the fluidics world with our primary mission being that “we digitalize fluidics,” meaning we develop and produce digital systems for precise fluid control and dosing based on the integration of precision fluidics, shape memory smart actuators and digital control electronics. We provide intelligent digital valves to mix, dose and detect fluids, combining embedded electronics, connectivity and smart actuators, enabling a new user experience and customer value through data.
Dolphin Fluidics and its team of outstanding engineers support each project from concept to production, integrating their expertise into customer applications.

Founded in 2013, F-Lab is an innovation center where highly qualified engineers and designers work together with universities, companies and experts on new technologies and materials to explore and develop ingenious solutions.
F-Lab aspires to be a model for future enterprising, in which people work together without hierarchies taking advantage of networking and new technologies to accelerate the innovation process.

We can offer technical solutions for those devices where hydraulic parameters are critical for safety and performance requirements. In the dialysis machines, the complex process of fresh dialysate continuous generation requires high quality standards. Fluid-o-Tech pumps, valves, and sensors are key to precisely manage fluids within the dialysis systems.
We are the ideal partner to develop fluidic solutions with our Customers for use in medical devices.
Thanks to our experience, know-how, commitment and passion we bring patients hope for a better future.

Frenova is a global site management organization dedicated to the success of clinical research.

Frenova delivers a network of research sites, a diverse patient population, and the expertise to get your trial up rapidly. We work with partner sites to enroll suitable patients for renal trials and studies of adjacent conditions. We also offer data analytics and licensing services, with access to one of nephrology’s largest longitudinal databases.

Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,925 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 333,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the Company focuses on expanding in complementary areas and in the field of critical care.

Founded in Asia-Pacific and driven by scientific expertise and operational excellence, George Clinical has been a leading, global clinical research organization for more than 20 years. With over 450 experienced people in 19 locations able to manage clinical trials in up to 70 geographies throughout the Asia-Pacific region, USA and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all phases, registration and post-marketing trials.

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology. We also have a special interest in nephrology and a commitment to the community impacted by renal disease. We are proud to be joining experts from around the world to discuss our science, create opportunities to connect with peers and deliver compelling content at this years ERA congress.

Please visit us at our booth, attend our industry symposia and spotlight sessions to learn more about GSK in nephrology.

BIOLIGHT was IPO since 2011 and is currently trading in the SHENZHEN STOCK EXCHANGE. Founded in 1993, BIOLIGHT is an internationally established leading provider in medical devices, medical consumables, and healthcare solutions. Including patient monitoring, emergency responds, hemodialysis renal care, and digital health homecare solutions.
BIOLIGHT, with headquarter in Zhuhai China, has a firm global RND, Marketing, Sales and Service presents. Biolight has established 8 researches and manufacturing plants, 12 subsidiaries, and oversea sales branches covering sales and services in Asia, Africa, Europe, North America, and Latin America expanding over 135 countries and counting. We established 7 high-techs manufacturing campus across China, located in Zhuhai, Tianjin, Liaoning, Chongqing, Changzhou, and Nanchang, with a combine area of 1,898,000 sqm conveniently and efficiently deliver quality products across the country and across the global.
BIOLIGHT maintains many long-term relationships with top universities, global health
organizations, health and social responsibility organizations actively involves in educations,
humanitarian mission, and patient care social projects. Fulfilling corporate social responsibility is
one of our core missions at BIOLIGHT. As an integral part of global economic ecosystem,
BIOLIGHT has made constant effort to contribute to public welfare in China and across, focusing largely in: access to education, access to technology, public health, and sustaining communities.
BIOLIGHT will continue to maximize the impact of our corporate responsibility programs by leveraging our unique company resource in biomedical engineering and digital health creating a platform to better focusing on generating values for our society.

ICU Medical is global leader offering clinically essential products and solutions that connect patients with caregivers through life-enhancing, innovative technology. Our robust portfolio features products for medication delivery, vital care, monitoring, and patient safety that help provide precision, accuracy, and reliability across the continuum of care.

Immundiagnostik AG is an internationally active diagnostics company developing and manufacturing innovative immunoassays and other analytical methods for routine and research. Immundiagnostik provides novel immunoassays and analytical tools focused on gastroenterology, nutrition, cardiovascular and renal diseases, bone metabolism, clinical immunology, oncology and more. We also offer laboratory support services, including proficiency testing, custom bulk packaging, and validation assistance. Visit Immundiagnostik to discover more about our products, services, and brands.

InBody is one of the worldwide leaders in body composition technology.

Non-invasive, fast and with little effort, InBody provides a comprehensive overview of a person’s overall health. Through data such as body fat mass, segmental muscle mass, body water and body mineral content, the result sheet provides a profound basis for the formulation of training and nutrition plans.

Furthermore, our digital solutions offer data transfer to the InBody CLOUD and InBody APP.

For more information, visit nl.inbody.com and get to know our life concept on site and take a measurement at our booth.

Infomed, worldwide player on blood purification devices offers complete solutions for chronic and acute renal replacement (homecare and hospital environment) and for plasma therapies. Active since more than 25 years, Infomed continuously innovates to create devices designed to reach your topmost needs. Dimi, our homecare dialysis device, is the partner for a new life at home. Dimi was thought to offer the freedom to provide the optimal treatment conditions fulfilling the patient requirements thanks to various therapies available such as peritoneal dialysis and hemodialysis.
Our products are adapted for adult, child and babies. We work for human well-being thanks to a large range of treatments available on our devices which include the “all in one” philosophy, as Infomed, we focus on you!

Established in 1989, Jafron Biomedical (ChiNext: JFSW) is a global provider of technology, product and therapy service in the hemoadsorption industry. With a market value of $7 billion, Jafron has three branches, 11 subsidiaries, one sub-subsidiary and medical foundation, insurance, etc.

Jafron has diligently devoted to the R&D, production and sales of blood purification products primarily in the hemoadsorption field for decades. It is dedicated to providing professional services to patients worldwide, covering ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, etc.

Jiangsu Solicitude Medical Technology Co., Ltd. (SMT Group) is a high-tech enterprise which focuses on the field of blood purification and biopharmaceutical. It has the strength of R&D, producing spinning systems, assembly systems, manufacturing finished products and selling a full range of filters, especially hollow fiber membrane, hollow fiber hemodialyzer and tangential flow filters.

Jiangxi Hongda Medical Equipment Group Ltd., established in 1987, is a leading manufacturer of disposable medical devices in China. It enjoys a convenient transportation which is 60KM far from Changbei Airport and 3KM away from bullet-train railway station.
Hongda Group has total assets of RMB 25billion and registered capital of RMB 428.88million, Total land area is approximately 600,000m2 including 60,000 square meters of 100,000 class cleaning room, with total staff nearly 6000.Owning the biggest production scale in China, its annual output of disposable medical products reaches 4 billion pieces. Hongda products are CE,ISO, SFDA approved. The domestic market share is up to 25%, Products have been exported to South America, Europe, Africa and Asia, etc, which is up to more than 80 countries.
Hongda Products cover eight categories: infusion and transfusion sets, syringes, puncture products, anaesthetic products, catheter products, examination and assistance products, hemodialysis products and protective products.

Jiangxi Sanxin Medical Technology Co., LTD was founded in 1997. It’s a national high-tech enterprise specializing in the research and development, manufacturing, sales, and service of medical devices.

Relying on the company’s advanced scientific and technological innovation platform, the company has excellent capability to transform scientific and technological achievements. At present, the company’s products cover three series: “blood purification, infusion, and cardiothoracic surgery”. As a top hemodialysis consumable manufacturer in China, Sanxin Medtec can provide a one-stop solution service for consumables and equipment.

JIHUA Medical Apparatus & Instruments Co., Ltd GUANGZHOU, established in 2000, currently located in Tianhong Technology Park, is the corporate enterprise win-win combined by Landwind Group. It is State key high and new technology enterprise by researching, developing, producing, selling, service and dialysis operations center for blood purify device and consumables.

Confirmed by ISO 13485, ISO 9001 and CE, JIHUA company occupy about 3000 square meters for production site and more than 60 experienced experts and technicians focusing on the production, R&D and services. So far, JIHUA products has been exported to more than 60 countries in Europe, Asia, South America and Africa countries. JIHUA company is guiding Chinese hemodialysis to overseas market.

Joline GmbH & Co. KG is an internationally operating medical technology company that sells a wide range of dialysis catheters, balloon catheters and stents for various indications worldwide. The long-established German company, which has been based in Hechingen for over 20 years, is divided into four successful divisions: Dialysis, Kyphoplasty, Cardiology and Stents & OEM division. All Joline medical devices are developed and manufactured in Germany.

When it comes to vascular access, Joline is your partner. Joline’s long- and short-term catheters have been specifically designed for use in extracorporeal blood purification procedures such as continuous renal replacement therapy, apheresis, and intermittent hemodialysis. Joline dialysis catheters are high-end, handmade products. They are assembled by hand in a complex manufacturing process.

Joline’s extensive experience in the field of catheter technology enables the company to offer a wide range of dialysis catheters. Premium quality, high value materials together with a unique functional tip design are characteristic of the Joline short-term dialysis catheter and long-term dialysis catheter.

KDIGO is a Belgian foundation committed to developing and implementing nephrology guidelines that improve patient outcomes on a global basis. KDIGO is independent, volunteer-led, self-managed, and accountable to the public and the people it serves.

Lepu Medical Technology (Beijing) Co., Ltd. was established in 1999. Lepu Medical is specialized in developing, manufacturing and distributing the high-tech medical devices and equipment. Today, Lepu Medical has grown into a global leading group company in the fields of cardiovascular interventions, structural heart diseases, neurointervention, cardiac rhythm management, anesthesia and critical care, in vitro diagnostics, ECG & patient monitoring, hemodialysis, orthopedics, skin care and general surgery. In 2009, Lepu Medical was successfully listed on ChiNext Shenzhen Stock Exchange market (stock code: 300003) with the market value of 10 billion USD. In 2022, Lepu Medical was listed on the SIX Swiss Exchange.

OCI Medical was founded in 2005 and became a subsidiary of Lepu Medical in 2012. lt is a high-techenterprise specializing in the R&D, production and sales of blood purification products. lts independently developed and produced PES hollow fiber membrane hemodialyzer has been widelyused in thousands of hospitals and dialysis centers, covering most hospitals in China, and exportedto dozens of countries overseas.

LiKAMED is a globally leading manufacturer of therapy chairs. Our products combine safety, quality, patient comfort, longevity and cost efficiency with design and more than 40 years of experience. In addition to a wide range of products, we also offer service and technical expertise to cover every needs of our customers all over the world.

As a market leader in the automation industry, Maider strives to provide its customers with advanced solutions for intelligent manufacturing. Maider offers three categories of systems: Intelligent equipment, IO4-enabled data management and software, and Process development, The Company has more than 700 peoples from different countries with high career experience supported by a strong and dedicated group of more than 200 technologists and engineers. Maider has obtained national innovation awards in China for its independently developed intelligent production/assembly systems for the assembly and production of infusion apparatus, medical IV catheters, tubular spinning lines, and hemodialyzer devices. Since its start, Maider has delivered and installed more than 3000 automated solutions for hundreds of customers around the world, including local and international medical companies such as Fresenius Kabi, Terumo, Shandong Weigao, and Kindly. We are focused and committed to the pursuit of excellence and will bring technological innovation, intelligent automation, and professional services to our customers.

Fluid management in hemodialysis and PD patients is at best challenging. Having the right tools can result in better management of patients, reduce staffing time and help with cost saving.

Maltron will showcase the BioScan touch i8 the most advanced Bioelectrical Impedance Body composition Monitor in its field. The first system, calibrated for Adults and infants. Accurate assessment of full body and direct segmental compartments are important to better understand the changes underway in these patients. Correct quantification of Dry weight, Malnutrition, loss of Muscle Mass, Excess Fluid, Intracellular, and Extracellular are some of the important parameters in patient care which are available in the touch i8.

The uniqueness of the BioScan provides you with the ability to perform comprehensive screening of different parameters. With Maltron’s patented technology used in the BioScan touch i8 you are able to monitor and track changes in both cellular and in Intravascular, Extravascular and Interstitial compartments giving you a complete understanding of the fluid shifts and the associated risks to the patient.

Come visit us at stand F.510 and learn more about our approach to better manage patient care.

A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. Based in Basel, Switzerland, MDPI has the mission to foster open scientific exchange in all forms, across all disciplines.

Our 439 diverse and open access journals, including 430 peer-reviewed journals and 9 conference journals, are supported by more than 295,000 academic experts who share our mission, values, and commitment to providing high-quality service for our authors. We serve scholars from around the world to ensure the latest research is freely available and all content is distributed under a Creative Commons Attribution License (CC BY).

MDPI publishes over 98 journals that are ranked as high impact within their fields. To view the current impact factors for MDPI journals (according to the Journal Citation Reports), please visit our yearly announcement page here: https://www.mdpi.com/about/announcements/6096.

With additional offices in Beijing, Wuhan, Tianjin and Nanjing (China), Barcelona (Spain), Belgrade and Novi Sad (Serbia), Manchester (UK), Tokyo (Japan), Cluj and Bucharest (Romania), Toronto (Canada), Kraków (Poland), Singapore (Singapore), Bangkok (Thailand) and Seoul (Republic of Korea), MDPI has published the research of more than 330,000 individual authors and our journals receive more than 25 million monthly webpage views.

MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and transdermal detection. MediBeacon’s use of proprietary fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable measurement of organ function.

The Company recently conducted the TGFR Pivotal study (NCT05425719). The TGFR Pivotal study is a Phase 3 open label, multi-center, safety and pharmacokinetic study of Lumitrace® (relmapirazin) and the use of the MediBeacon Transdermal GFR Measurement System (TGFR) in normal and renal compromised subjects for the evaluation of kidney function.

In preclinical research the MediBeacon transdermal GFR system tracks Glomerular Filtration Rate (GFR) without restraining the animal. The system obviates the need for blood sampling, urine collection, and laboratory assays thus enabling superior trial design. The result is enhanced kidney therapeutic assessment, nephrotoxicity evaluation and fundamental understanding of kidney function in animals. For more information, please visit: www.medibeacon.com

Medica Group is a leading manufacturer of medical and water purification device operating since 1985 in the biomedical district of Mirandola in Italy.
BUSINESS UNITS:
– Medical Division: disposable and equipment for blood purification, cardiology, organ transplant, bioregenerative medicine,
urology, gastroenterology and oncology.
– Water Division : ultrafiltration and microfiltration from home drinking to hospital and pharma applications.
– Automation: assembly equipment for medical device manufacturers.
STRENGTHS:
– Vertical integration from R&D to manufacturing for disposable, medical equipment and assembly technology.
– Know how integration makes Medica Group a strategic partner and a global solution provider for many multinational
corporation.
– Hollow fiber spinning technology for blood and water purification.

Medcomp® develops, manufactures, markets and supports cutting-edge vascular access devices and accessories to meet the clinical needs of the medical industry, particularly in the fields of interventional medicine and dialysis. Our company’s engineering and applications expertise provides superior products whose progressive designs accommodate advances in medicine and whose quality anticipates the requirements of our professional clients and the patients they serve. Currently one of the world’s largest manufacturers of dialysis and centrally terminating venous catheters, Medcomp is, and always has been, on the cutting edge of new vascular access device technologies.

MEDICE is a dynamic, fully integrated, third-generation family business. Developing high-quality medicines, manufacturing them at our own sites in Germany and distributing them in our home market of Germany and worldwide – that is what drives us at MEDICE and is therefore at the heart of the Health Family.

The world and the healthcare market have been changing radically for years. Patient-individualized therapy and patient empowerment, a focus on nature, environmental protection and sustainability are key topics that are completely reorganizing the world. New therapies and services are emerging, growth in new areas is accelerating and is being fuelled by increasing digitalization. We have responded to this world by transforming ourselves into the MEDICE Health Family.

The aim of the Health Family is to become a leading developer and provider of a wide range of healthcare solutions. In future, we will develop suitable prevention and treatment concepts for every stage of the disease, from the onset to acute symptoms, in which pharmaceutical, digital and nutritional expertise are intertwined and interwoven in the sense of innovative prevention and therapy management.

In line with this approach, the company possesses three interdisciplinary fields of expertise:

1. Pharmaceutics
2. Digital Health
3. Nutritional Medicine

We constantly analyse the needs of doctors, pharmacists and patients in every field of clinical indication to develop evidence-based preventative and therapeutic solutions using a continuous and overarching innovation process that incorporates our interdisciplinary fields of expertise. MEDICE has opened a whole new dimension of medical care with these continually updated healthcare solutions. Our aim is to deliver a level of therapy to patients and their relatives in the future that is far beyond what can currently be achieved.

MEDIKIT is a leading Japanese manufacturer of medical devices for vascular access such as plastic fistula cannulas and intravenous catheters along with interventional instruments. With more than 50 years of experience, we support hospitals and healthcare services around the world as a strong and reliable technology and service partner. MEDIKIT develops innovative products – like our plastic fistula cannulas with full cover safety mechanism – with a high commitment to quality, and thus intends to contribute to the improvement of treatments and future medical technologies. Our mission is to reduce the burden on patients during the treatment and at the same time improve safety for medical staff. In this way, we want to be of help to the well-being of the societies in which we live.

As an internationally operating system supplier for medical data processing, MedVision stands for quality and innovation. For over 30 years, we have been developing efficient and economical standard application software for the medical sector.

Our information systems offer a multitude of applications and integrated solutions thus enabling more efficient and economic treatment, care and administration of patients in an unprecedented way. Powerful monitoring, analysing and reporting functionalities optimise the complex processes in medical institutions. This is complemented by interfaces to hospital or laboratory information systems.

With the NEPHRO information system and the accredited QuaNT and SiQuiD benchmarking analysers, MedVision is one of the leading suppliers for nephrological information systems in Germany. OEM versions of our information systems are sold worldwide by our co-operation partners.

Our customers are outpatient clinics, community health centres, doctor’s surgeries and dialysis centres as well as speciality departments of hospitals – individually run or as part of operating companies or associations. Next to our considerable customer base in Germany, we are also providing services for a constantly growing number of business partners both in Europe and Asia.
Our customised hardware and software solutions and our extensive experience in realising projects predestine us as competent IT partner in the public health sector.

Supported by an investment from Medtronic, Inc. and DaVita, Inc.,
Mozarc Medical is a company solely focused on developing breakthrough kidney health technology.
Empowering providers with a holistic, comprehensive portfolio, from access through treatment.
Providing caregivers with unwavering support. And always putting the patient first.

Home

As the first major Canadian company to enter the dialysis market, NephroCan is a fully integrated product and service provider for patients living with End Stage Renal Disease (ESRD). Comprised of nephrologists, nurses, engineers, quality management professionals, and a vast R&D team, we offer reliable, cost-effective products.

NephroCan was founded on the principle that every hemodialysis patient deserves to have the best quality treatment built around their specific needs, irrespective of circumstance. We are committed to transforming renal care and believe that hemodialysis should be equitable, accessible, and affordable for all.

Nephrokit is an entity of Gergonne Group whose main objective is to provide to dialysis caregivers solutions that enable the rationalization and standardization of techniques for securing needles and catheters for hemodialysis and reducing bleeding during and after dialysis session.

———-

Nephrokit est une entité du groupe Gergonne qui a pour principal objectif de fournir au professionnels de la dialyse des solutions permettant de rationnaliser et de standardiser les techniques de sécurisation des aiguilles et des cathéters pour l’hémodialyse mais aussi de réduire les temps de saignements pendant et après la séance de dialyse.

Nephrolyx offers a precise and rapid measurement of the kidney function (true GFR). We provide hospitals and laboratories with an In-Vitro Diagnostic Test and a digital platform to measure the true GFR within only a few hours. For the first time, physicians can detect renal diseases using the highest accuracy of GFR measurement and adapt an optimal treatment plan for patients. Especially nephrology, oncology, transplantation, and ICU patients can benefit from rapid and precise diagnostics.

The Nephrolyx IVDx is indicated for the in-vitro quantitative determination of serum iohexol concentration and calculation of the glomerular filtration rate (GFR). The principle of the test is based on Ultra-High-Performance-Liquid Chromatography using Ultra-Violet light.

Proprietary technology from Nephrolyx helps to improve treatment success for kidney patients. Given its low component cost, the Nephrolyx IVDx can also significantly enhance the performance of the entire healthcare system.

NextKidney’s mission is to develop and commercialize the Neokidney home hemodialysis device. Placing the patient and his quality of life at the center of its approach, the company uses innovative technologies to offer a safe, practical, and easy-to-use solution as quickly and widely as possible throughout the world.

Nightingale Health offers affordable metabolomics and scalable remote blood collection. Measure more than 250 biomarkers that cover core human metabolism, including 39 clinically validated biomarkers from just €24 per sample. As the only ‘omics technology measured in the whole UK Biobank, replicate your findings in one of the world’s biggest health research datasets. You can also use our end-to-end remote collection service for participants to take blood samples at home, and further expand your multi-omic study possibilities. Learn more: research.nightingalehealth.com

Optimising patient care is at the core of our ethos.

NIKKISO, a pioneer in Renal Replacement Therapies, strives to advance complex medical technologies that optimise patient care in End-stage Renal and Critical Care areas. Through our commitment to improving clinical efficiency and patient QoL, Nikkiso has built a global reputation for unparalleled quality and innovation. This is mirrored by technical and medical solutions integrated in NIKKISO’s medical and health care devices.

DBB-EXA series, our dialysis machines for online hemodialysis (online HD) and online hemodiafiltration (online HDF), provide high-end usability and a wide range of value-oriented solutions and features, achieved by integrating decades of NIKKISO’s expertise in Renal Replacement Therapies.

DBB-EXA ES is today the first launched single pump dialysis machine that performs online priming, online bolus and online wash back in HD treatments.
The integrated automatisms of the DBB-EXA (e.g. automatic priming, treatment start and wash back), and its proven reliability, contribute to the noticeable success of the DBB-EXA in Western Europe countries, underlined by growing market shares and customers satisfaction.

Aquarius System with Aquarius+ software uses accuracy and simplicity to deliver adult and low volume Acute Blood Purification treatments whether using core CRRT or TPE in addition to adjunctive hemoadsorptive therapies for sepsis / toxin removal regardless of anticoagulant needs of the patient with a single line set. This is further captured in the launch of ProLUNG; a minimally invasive CO2 Removal system using Aquarius.

Nipro Renal Care is part of Nipro Corporation Japan, a leading global healthcare company established in 1954. With over 36.000 employees worldwide, Nipro serves the Medical Device, Pharmaceutical, and Pharmaceutical Packaging industries.

Nipro Renal Care is a global market leader with over 5 decades providing renal solutions for dialysis and dialysis-related treatment. We specialize in developing dialysis machines, water treatment systems, and a comprehensive portfolio of disposable medical equipment. In order to address the needs of patients, healthcare professionals, and procurement managers alike, Nipro Renal Care is driven by innovation and patient safety to offer the highest quality products that optimize time, effort, and costs.

Live Longer. Live Better.
Caring to improve patient outcomes and quality of life for all!

Nova Biomedical is a world leader in point of care and critical care in vitro diagnostics. We offer products with a renal function panel, that can be used either within or outside the hospital setting.
• Stat Profile Prime Plus® blood gas critical care analyzer with a kidney function panel. Using maintenance-free sensors, the system offers a comprehensive 22-test blood gas menu including tests for iMg, Urea, Creatinine, estimated Plasma Volume (ePV) and Co-oximetry.
• StatSensor® Creatinine measures capillary whole blood creatinine and calculates eGFR to enable a rapid assessment of renal function prior to the administration of nephrotoxic drugs in areas such as Accident & Emergency, Radiology or Oncology.
• NovaMax Pro eGFR® is an important new tool to improve kidney care through kidney function screening and early detection of kidney disease in point-of-care settings outside the hospital. The Nova Max Pro measures blood creatinine and calculates estimated glomerular filtration rate (eGFR), two important indicators of overall kidney function, from a tiny 1.2 microliter capillary fingerstick blood sample in just 30 seconds.
• Allegro®, a compact, capillary blood analyser offering a kidney function panel designed for use in primary care or hospital clinics. The system can measure HbA1c, Lipids, Glucose, Creatinine, CRP and PT/INR from capillary whole blood, plus Urine Albumin and Creatinine; with all tests using disposable cartridges and test strips.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170 countries.

Otsuka Pharmaceutical Development Company, Inc

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: ‘Otsuka-people creating new products for better health worldwide.’

Our 47,000 employees channel their passion and commitment into aiming to improve the health of our patients, with a focus in Europe on therapies in mental health, nephrology, haemato-oncology and rare diseases.

OPE-NPR-2400013 v1.0
Date of preparation: April 2024

Leader in home hemodialysis, Physidia is a French company specialized in developing, manufacturing and commercializing an innovative equipment and disposables for delivering frequent home hemodialysis treatment.
Physidia’s innovations are based on several technological breaking points, offering a robust, portable and connected device, whilst ensuring a performing treatment in total autonomy.

Created by an expert team, Physidia’s S³ monitor has been specifically developed to respond to the needs of simplicity and safety of ESRD patients in home hemodialysis. The Physidia S³ monitor offers the treatment of renal failure with daily dialysis sessions of 2 to 3 hours 5 to 6 times a week.
Daily hemodialysis is recognized today as the most physiological therapy for the patient experiencing renal failure as this therapy provides outcomes close to natural kidney functioning.

Physidia is present today in 16 countries, operating directly in France and through distributor partners in the rest of Europe and middle east. Since its origin, the principal ethos of the company has been innovation with exceptional service by providing comfort, freedom and security to every patient.

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense Alarm System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company’s technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.

Reliant Glycosciences, LLC is a biotechnology company that focuses on developing diagnostic and prognostic tools for patients with IgA nephropathy. Reliant was spun-out in 2016 from UAB. Reliant’s goal is to develop marketable assays for these IgAN-specific biomarkers so that they can be available to the IgAN research community as well as pharmaceutical companies interested in developing treatments for IgAN. Reliant’s goal is to have an impact on the disease itself and the treatment.

The Renal Traveller is an integrated web and mobile app tailored for traveling dialysis patients where they can easily locate and book clinics for their treatments. Our user-friendly interface on both web and mobile app platforms allows dialysis clinics to:

✨ Showcase their facility with detailed profiles and real-time availability.
✨ Attract traveling dialysis patients through an interactive map and advanced filters.
✨ Secure bookings with an efficient and straightforward reservation process.

Riva Engineering Water Treatment Systems Inc., established in 2006, is one of Turkey’s leading companies in the field of water treatment systems. Our company specializes in water treatment systems for the medical and industrial sectors.

Our foundation was laid in 2006, and over this period, we have gained a prestigious position among the industry’s top names. Initially, we focused on industrial water treatment systems. However, within a short span of time, we expanded our expertise to the medical sector, achieving significant progress.

Since its inception, our company has grown rapidly and developed into one of the leading firms in the industry, known for its excellence. Our expertise in medical water treatment systems was one of the primary areas we initially focused on, and we took significant steps in ensuring customer satisfaction through superior solutions in this field.

As a strategic move, we integrated our extensive experience in the medical field into our business portfolio within a short timeframe, further expanding our range of services. In line with this, we positioned our expertise in the medical sector at the core of our research and development (R&D) efforts, enabling us to provide customers with state-of-the-art technology-based solutions. This initiative elevated us as a prominent factor in the healthcare sector, reinforcing our brand through a customer-centric approach.

Our gained expertise in the medical sector, in particular, enhanced our capacity to develop innovative medical devices and solutions. With a firm grasp on the latest emerging technologies, we leave a mark in the healthcare sector by delivering personalized and effective solutions to our customers. Backed by a strong foundation in the medical domain, we take pride in delivering impactful and high-quality services in the healthcare sector.

We hold a leadership position in the healthcare sector as well. Leveraging our in-depth specialization in the medical field, we provide innovative medical devices and solutions to meet the comprehensive needs of healthcare service providers. This dual competence allows us to maintain a robust presence as an effective and pioneering player in both the industrial and healthcare sectors. Just as in the healthcare sector, we aim to be a leader in the industrial sector through RİVATEC.

Today, despite our modest beginnings in 2006, we retain our respected position in the industry and continue to grow steadily. With our customer-centric approach, commitment to quality services, and expanding expertise in the healthcare sector, we are determined to embark on successful projects in the future and maintain our role as an industry leader thanks to the foundation laid by RİVATEC.

The year 2018 marked a significant milestone for RIVAMED. Under the RİVAMED brand, we take great pride in being the sole domestic manufacturer of hemodialysis water treatment systems with compliance to Directive 93/42/EEC and possessing the CE certificate. Setting reliability and quality standards in the healthcare sector, we assume a pioneering role in meeting the highest-level needs of healthcare institutions in areas such as hemodialysis, sterilization, neutralization, and disinfection.

Our manufactured systems meet ISO standards and European Pharmacopoeia requirements. Additionally, for the industrial water treatment and wastewater treatment systems produced under the name RİVATEC, we hold CE certification, ensuring a safe and suitable user experience. Walking the path driven by the global water scarcity issue, we take action to provide superior service to dialysis patients worldwide, minimize kidney failure, ensure the continuity of clean and purified water, and take pride in exporting to 52 countries. With determined strides towards the goal of “Save Water, Save Life,” we work and evolve to become the sole destination for every sector in need of clean and healthy water.
RİVAMED aims to provide unique and the most suitable solutions for every project with its expert team. By collaborating with important public institutions such as the Ministry of Health, the Ministry of Justice, the Ministry of Treasury and Finance, the State Hydraulic Works (DSI), the Turkish Armed Forces (TSK), and the General Directorate of Highways (KGM), we are making strides in high-quality and sustainable water treatment projects.

Our headquarters and manufacturing facility are located in Ankara. Additionally, with regional offices and a technical service network in Istanbul, Antalya, Gaziantep, Ordu, Kayseri, and Van, we offer services across an extensive geographical area throughout Turkey. Since 2018, we have been engaging in international projects, continuing to provide environmentally friendly solutions in the field of water treatment to various regions around the world. Within the seven geographical regions of Turkey, and within each province (such as Adana, Adıyaman, Afyonkarahisar, Ağrı, Aksaray, Amasya, Ankara, Antalya, Ardahan, Artvin, Aydın, Balıkesir, Bartın, Batman, Bayburt, Bilecik, Bingöl, Bitlis, Bolu, Burdur, Bursa, Çanakkale, Çankırı, Çorum, Denizli, Diyarbakır, Düzce, Edirne, Elazığ, Erzincan, Erzurum, Eskişehir, Gaziantep, Giresun, Gümüşhane, Hakkari, Hatay, Iğdır, Isparta, İstanbul, İzmir, Kahramanmaraş, Karabük, Karaman, Kars, Kastamonu, Kayseri, Kırıkkale, Kırklareli, Kırşehir, Kilis, Kocaeli, Konya, Kütahya, Malatya, Manisa, Mardin, Mersin, Muğla, Muş, Nevşehir, Niğde, Ordu, Osmaniye, Rize, Sakarya, Samsun, Siirt, Sinop, Sivas, Şanlıurfa, Şırnak, Tekirdağ, Tokat, Trabzon, Tunceli, Uşak, Van, Yalova, Yozgat, Zonguldak), we provide 24/7 service for hemodialysis water treatment systems, prioritizing patient health.

As RİVAMED, with the expansion of our global network, we aim to establish solid and valuable collaborations with our esteemed customers at the medical sector-focused exhibitions and events we participate in. Especially with our hemodialysis water treatment systems, we operate with the mission of providing the highest level of quality and service to patients undergoing dialysis and suffering from kidney failure.

With an open approach to technological innovations and a focus on “Quality in Healthcare,” we continue to maintain a pioneering and reliable position in the field of water treatment. Our goal is to provide our customers with the best service, and we strive to advance our industry leadership and achievements with each passing day.

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Rontis, a Switzerland based multinational healthcare corporation, was established in 1986 by a group of leading professionals with lengthy experience in the wider healthcare sector and a vision to provide the most innovative & trustworthy solutions in the market, aiming to become an international leader in the global healthcare industry. We have a history in R&D & manufacturing of Medical Devices, Pharmaceuticals and Dialysis Services.
Medical Devices: we produce disposables for Nephrology, Liquid Administration, as well as products for Interventional Cardiology & Radiology.
Pharmaceuticals: Rontis has a vertically integrated manufacturing system that is supported by the R&D division.
We also provide Original Equipment Manufacturer (OEM) and custom-made solutions.
Website: www.rontis.com

Connecting people and science since 1890, Karger provides scientists, healthcare professionals, patients, and the broader public with reliable and tailored information in Health Sciences. Building upon a publishing portfolio of more than 100 reputable scholarly journals and the award-winning Fast Facts medical info series, Karger excels in medical education and omnichannel HCP engagement in multiple formats, including 3D animations, podcasts, AR/VR environments, and more. Academic institutions and both medical affairs and pharma marketing teams in the corporate space entrust Karger with their most demanding communication challenges. Independent and family-led in the fourth generation by Chairwoman Gabriella Karger, Switzerland-based Karger is present in 15 countries with a team of 200 dedicated professionals worldwide.

Samsung Bioepis is a biopharmaceutical company dedicated to accelerating access to biologic medicines by bringing high-quality, clinically proven biosimilars to patients who need them

Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives.
Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

/

SOLUDIA Maghreb
In 1998, Soludia Maghreb laboratory was born from the successful technology transfer from Soludia France to its subsidiary Soludia Maghreb.

Soludia Maghreb Knew how to use Soludia France’s expertise in de hemodialysis field, and orientated its strategic choices towards:

Proposing quality products, recognized by the European level since 2006, ISO certification 13485 and ISO 9001.
Insure the development of new formulae to personalize the treatment of the patients.
Developing new packagings of products to meet better the needs of hemodialysis centers in Morocco.
Soludia maghreb offers you ideally suited solutions to every haemodialysis center namely acid central, 5liter acid bag, cartridge of bicarbonate powder etc.

Conscious of the impacts of competitors and market globalization, which demand a high level of efficiency and latest technologies, we continue to fulfill the challenge.

At STADA, our purpose of Caring for People’s Health as a Trusted Partner means supplying a broad portfolio of high-quality pharmaceuticals across three business units. Specialty Pharmaceuticals provides tailored treatment options for specific and unmet patient needs, including orphan drugs for rare diseases and six marketed biosimilars, in therapeutic categories including nephrology, neurology, oncology, immunology and ophthalmology. Generics enable access to well-proven treatments as Europe’s fourth-largest supplier. A broad range of Consumer Healthcare brands provides patients and consumers with appealing options to manage their own health.
Headquartered in Bad Vilbel, Germany, STADA sells its products in approximately 120 countries worldwide. In financial year 2022, STADA achieved group sales of EUR 3,797.2 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 884.7 million. As of 31 December 2022, STADA employed 13,183 people worldwide.

SUBMED specializes in producing a range of products specifically designed for the dialysis field. SUBMED range includes dialysis fistula and catheter on/off kits, catheter protection and shower pouches, and catheterization kits. These products have gained a reputable market share throughout Europe and exported over 40 countries.

At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised biopharmaceutical company, we provide sustainable medicines to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a rare expertise and a strength in access that allows us to be a partner in care for those with high unmet needs. Sobi headquarters are located in Stockholm, Sweden.

In 2000, TauroPharm GmbH was founded as a German company specialising in medical devices with antimicrobial, antibiofilm and antiocclusive efficacy.

Based on its innovative products, we aim to develop more effective ways to prevent catheter-associated complications – ranging from blood clotting to fatal infections. Throughout this process, improving the patient’s quality of life remains our top priority.

Since there is an urgent need for our products, especially in light of the steadily increasing number of antibiotics-resistant pathogens, TauroLock is recommended in interdisciplinary national and international guidelines. All products have been investigated in independent scientific studies with excellent study results.

Boehringer Ingelheim and Eli Lilly and Company
The Boehringer Ingelheim and Lilly Alliance leverages the strengths of two of the world’s leading pharmaceutical companies. By joining forces, the companies demonstrate their commitment, not only to the care of people with type 2 diabetes, but also to address areas of unmet medical need like heart failure and chronic kidney disease.

About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units, Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn.

Toray Medical Co., Ltd. is a member company of Toray Group, specializing in healthcare field business.
Toray is a leading manufacturer of synthetic fibers and dedicated to the development of dialysis
products under its corporate slogan, “Innovation by Chemistry”. Toray supports high quality and
advanced medical care with bio-compatible polymethylmethacrylate dialyzer “FILTRYZER”, high flux
polysulfone dialyzer “TORAYSULFONE”, “TORAYLIGHT” and dialysis machine.

Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.

Vertex Pharmaceuticals, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases. Our therapy areas focus on cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia and we continue to advance its research in these diseases and several other serious diseases.

Vivisol, a company within the SOL Group, has been active for over 35 years in homecare services and has established itself as one of the leading “Homecare Providers” in Europe. Thanks to the widespread presence of its territorial branches, Vivisol assists over 650,000 chronic and multi-chronic patients worldwide, elderly individuals, and numerous pediatric cases with complex and often rare conditions. Patients are assisted by VIVISOL on behalf of the healthcare systems of different countries, outside of the protected hospital environment. VIVISOL services cover many therapeutic areas, including Respiratory care, nursing, infusion therapies, advanced homecare, home dialysis, and assistive devices development, production, and distribution.

WEGO Blood Purification Group was established in 2004 and focusing on the field of blood purification. Around 5100 employees are serving more than 5000 customers worldwide. It has gradually become a outcome international industrial group with first-class technology and quality.

WEGO Blood Purification Group owns 14 subsidiaries and joins force together with two major international medical group companies, Terumo and Nikkiso, to provide hemodialysis, peritoneal dialysis and
hemodialysis service business. WEGO Blood Purification Group has achieved the coverage of the whole industrial chain of products and services related to blood purification. We are devoted to providing top-quality products and treatment to our patients worldwide.

WEGO Blood Purification Group belongs to WEGO Group which is one of the top 500 enterprises in China and employing more than 30,000 people worldwide. WEGO Group has more than 80 subsidiaries which covers 12 industries in Blood Purification, Orthopedics, Medical Equipment, Pharmaceuticals, Cardiac Consumables, Medical Business and Surgical Robotics etc.

/

/

EuroPD regularly attracts between 700 to 1,000 participants from over 60 countries, making it the definitive meeting for PD specialists in Europe and beyond and provides education in all aspects of the treatment and advancement of PD.
We are planning a face-to-face meeting in 2023 – Find out more details by visiting our website www.europd.com

The foundation of our activities is the health and well-being of patients with Chronic Kidney Disease (CKD), and their carers. Those on dialysis treatment and kidney transplant recipients make up the vast majority of patients but we also include those in the early stages of kidney disease who are sometimes called pre-dialysis patients. Part of our brief is promoting early detection of kidney disease.

EKPF represents over 75 million of people with kidney health conditions in Europe. Its membership brings together 27 national kidney patients federations from 26 different countries across Europe. Its mission is to improve:

Voice
Choice
Involvement
Safety
Autonomy
Quality of life
Innovation and research

European Society for Paediatric Nephrology (ESPN)

Become a member

The European Society for Paediatric Nephrology (ESPN) was founded in 1967 with the goal of diffusing knowledge and improving the treatment of children with kidney diseases.

ESPN brings together clinical professionals and researchers that operate in the field of Paediatric Nephrology throughout Europe. ESPN has approximately 700 active members.

Our Society has multiple activities including the annual congress, collaborative research projects, teaching courses, workshops, webinars, clinical practice guidelines, a three-year curriculum in Paediatric Nephrology, and a EU-certified board examination in Paediatric Nephrology among others. ESPN working groups and task forces provide focused research and educational opportunities.

ESPN is the official European partner of the International Pediatric Nephrology Association (IPNA) (https://theipna.org) and is closely associated by mutual agreement with the European Renal Association (ERA) (https://www.era-online.org).

IPNA is a global charitable organization managed by an all-volunteer council representing every continent in the world. IPNA operates under the premise that all children deserve to be healthy and receive optimal treatment and care for kidney disease regardless of their economic level or political choice. IPNA collaborates with seven regional pediatric nephrology societies around the world focusing on education and training programs.

IPNA´s mission is to lead the global efforts to enhance the care for all children with kidney disease through advocacy, education, training and research.

The International Society for Peritoneal Dialysis aims to increase the global uptake, promote quality practice, and achieve optimal outcomes of peritoneal dialysis through enhanced advocacy, research, and education, in order to improve the health and well-being of people living with end-stage kidney disease or suffering from acute kidney injury.

The mission of the JSN is to aid in the practice and study of Nephrology. In order to achieve this the JSN conducts a range of activities. These include holding regular meetings as a forum for the diffusion of information, producing regular journals, coordinating clinical research, promoting cooperation with related societies in Japan and internationally, as well as providing recognition to those who have made significant contributions in the field of Nephrology.

/

PKD International is a global alliance of patient organizations committed to finding a cure for Polycystic Kidney Disease (PKD). Our mission is to improve the lives of individuals affected by PKD worldwide. With a focus on uniting patients and medical experts dedicated to ending PKD, we strive to provide access to the latest information, support, and opportunities for involvement in research and clinical trials. Together, we lead the charge against PKD, advocating for the 12.5 million people worldwide affected by this disease.

/